Dynamic prediction of treatment response in late-life depression

American Journal of Geriatric Psychiatry

Volumn 22, Issue 2, 2014, Pages 167-176

  Joel, Ian ^a   Begley, Amy E ^a   Mulsant, Benoit H ^b   Lenze, Eric J ^c   Mazumdar, Sati ^d   Dew, Mary Amanda ^a   Blumberger, Daniel ^b   Butters, Meryl ^a   Reynolds, Charles F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Decision trees; Dynamic remission prediction; Late life depression

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; PLACEBO; VENLAFAXINE;

AGED; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; FEMALE; HUMAN; LATE LIFE DEPRESSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; PRACTICE GUIDELINE; PREDICTION; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEX DIFFERENCE; SIGNAL DETECTION; TREATMENT DURATION; TREATMENT RESPONSE;

DECISION TREES; DYNAMIC REMISSION PREDICTION; LATE-LIFE DEPRESSION;

AGE OF ONSET; AGED; AGED, 80 AND OVER; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SIGNAL DETECTION, PSYCHOLOGICAL; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84893109478     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2012.07.002     Document Type: Article

References (41)

1. Mulsant BH, Ganguli M: Epidemiology and diagnosis of depression in late-life. J Clin Psychiatry 1999; 60(suppl):9-15
2. Bruce ML, McAvay G: Epidemiology of psychiatric disorders in late life. Prim Psychiatry 1998; 5:59-65
3. Thomas L, Mulsant BH, Solano FX, et al: Response speed and rate of remission in primary and specialty care of elderly patients with depression. Am J Geriatr Psychiatry 2002; 10:583-591
4. Whyte EM, Basinski J, Farhi P, et al: Geriatric depression treatment in non-responders nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65(12):1634-1641
5. Flint AJ, Rifat SL: Maintenance treatment for recurrent depression in late-life. Am J Geriatr Psychiatry 2000; 8:112-116
6. Whyte EM, Dew MA, Gildengers A, et al: Time course of response to antidepressants in late-life major depression: therapeutic implications. Drugs Aging 2004; 21(8):531-554
7. Dombrovski AY, Szanto K, Siegle GJ, et al: Suicidal Elderly Discount Future Rewards. Vancouver, Canada, Biological Psychiatry, 2009
8. Mulsant BH, Houck PR, Gildengers AG, et al: What is the optimal duration of a short-term antidepressant trial when treating geriatric depression? J Clin Psychopharmacol 2006; 26(2):113-120
9. Dew MA, Whyte EM, Lenze EJ, et al: Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry 2007; 164(6): 892-899
10. Gildengers AG, Houck PR, Mulsant BH, et al: Trajectories of treatment response in late-life depression: Psychosocial and clinical correlates. J Clin Psychcopharmacol 2005; 25(suppl 1):S8eS13
11. Andreescu C, Lenze EJ, Dew MA, et al: Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry 2007; 190:344-349
12. Tew JD, Mulsant BH, Houck PR, et al: Impact of prior inadequate treatment exposure on response to antidepressant treatment in late life. Am J Geriatr Psychiatry 2006; 14(11):957-965
13. Dew MA, Reynolds CF, Houck PR, et al: Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54: 1016-1024
14. Szanto K, Mulsant BH, Houck P, et al: Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003; 60(6):610-617
15. Driscoll HC, Basinski J, Mulsant BH, et al: Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 2005; 20:661-667
16. Shelton RC, Hollon SD, Wisniewski SR, et al: Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STARD Report. CNS Spectr 2009; 9:487-498
17. Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptictreated patients. Acta Psychiatr Scand 1987; 334(suppl):1-100
18. Reynolds CF, Dew MA, Martire LM, et al: Treating depression to remission in older adults: a controlled evaluation of combined interpersonal psychotherapy versus escitalopram with depression care management. Int J Geriatr Psychiatry 2010; 25: 1134-1141
19. Sackeim HA, Roose SP, Lavori PW: Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biol Psychiatry 2006; 59(6):483-492
20. Muzina DJ, Chambers JS, Camacho TA, et al: Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care 2011; 17(12):793-801
21. Trivedi MH, Baker SM: Clinical significance of monitoring early symptom change to predict outcome. J Clin Psychiatry 2001; 62(Suppl 4):27-33
22. Andreescu C, Mulsant BH, Houck PR, et al: Empirically derived decision trees for the treatment of late-life depression. Am J Psychiatry 2008; 165(7):855-862
23. Alexopoulos GS, Meyers BS, Young RC, et al: The vascular depression hypothesis. Arch Gen Psychiatry 1997; 54(10): 915-922
24. McLennan SN, Mathias JL: The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review. Int J Geriatr Psychiatry 2010; 25(10):933-944
25. Berman RM, Marcus RN, Swanink R, et al: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007; 68(6):843-853
26. Marcus RN, McQuade RD, Carson WH, et al: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28(2): 156-165
27. Nelson JC, Delucchi K, Schneider LS: Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008; 16(7):558-567
28. First M, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P). New York, New York State Psychiatric Institute, 1995
29. Beck AT, Kovacs M, Weissman A: Assessment of suicidal intention: The Scale for Suicide Ideation. J Consult Clin Psychol 1979; 47:343-352
30. Derogatis LR, Melisaratos N: The Brief Symptom Inventory: an introductory report. Psychol Med 1983; 13(3):595-605
31. Meyer TJ, Miller ML, Metzger RL, et al: Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990; 28(6):487-495
32. Miller MD, Paradis CF, Houck PR, et al: Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41(3):237-248
33. Randolph C, Tierney MC, Mohr E, et al: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998; 20(3): 310-319
34. Delis DC, Kaplan E, Kramer JH: Dellis Kaplan Executive Function System Examiner's Manual. San Antonio, TX, The Psychological Corporation, 2001
35. Oquendo MA, Baca-Garcia E, Kartachov A, et al: A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry 2003; 64(7):825-833
36. Nierenberg AA, McLean NE, Alpert JE, et al: Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995; 152(10):1500-1503
37. Szegedi A, Muller MJ, Anghelescu I, et al: Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003; 64(4):413-420
38. Szegedi A, Jansen WT, van Willigenburg AP, et al: Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a metaanalysis including 6562 patients. J Clin Psychiatry 2009; 70(3): 344-353
39. Nelson JC, Zhang Q, Deberdt W, et al: Predictors of remission with placebo using an integrated study database from patients with major depressive disorder. Curr Med Res Opin 2012; 28(3): 325-334
40. Rush AJ, Trivedi MH, Ibrahim HM, et al: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54(5):573-583
41. Kroenke K, Spitzer R: The PHQ-9: a new depression and diagnostic severity measure. Psychiatr Ann 2002; 32:509-521